Summary
- Profile Type
- Business request
- POD Reference
- BRFR20250516021
- Term of Validity
- 16 May 2025 - 16 May 2026
- Company's Country
- France
- Type of partnership
- Commercial agreement
- Investment agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
-
The company is developing a drug to treat traumatic brain injury using a molecule extracted from marine macroalgae. The company works to valorise extraction by-products, ensuring a sustainable, biotech-driven approach to neurorepair.
A commercial partner is needed to
• Characterize and develop product lines derived from these co-products
• provide industrial scaling and formulation expertise
• Navigate regulatory landscapes
• Co-invest in industrial valorization platforms - Full Description
-
Our company is a biotechnology company focused on developing innovative therapies derived from marine algae. Its lead program targets the treatment of traumatic brain injury (TBI), a major public health concern (50m people/year) with limited therapeutic options. The company has identified and isolated a unique bioactive molecule, a polysaccharide, from marine macroalgae with potent immunomodulatory properties. This molecule is capable of reprogramming the immune response following a traumatic brain injury, reducing harmful neuroinflammation and promoting neural repair mechanisms.
TBI often triggers a cascade leading to immune deficiency that exacerbate damage to brain tissue. Our approach is to modulate this response at a critical window post-injury, aiming to limit secondary damage and support regeneration. Preclinical studies have shown that the compound improves immune status, clinical score and skull and brain regeneration in TBI models, while demonstrating a good safety profile.
In parallel, the company is committed to sustainable innovation. The company is developing methods to valorise the co-products of the macroalgae extraction process, converting what would otherwise be waste into valuable ingredients for the cosmetic, nutraceutical and other sectors.
With its multidisciplinary expertise in marine biology, immunology, and drug development, our company is positioning itself as a pioneer in marine-based therapeutics for central nervous system injuries. The company’s drug candidate holds promise not only for TBI patients but also for broader applications in neuroinflammatory and neurodegenerative disorders. - Advantages and Innovations
-
First-in-class marine-derived drug for TBI.
The molecule developed by our company is sourced from marine macroalgae, a completely novel origin for neurotherapeutics and no current treatment exists that directly modulates the immune response to promote repair after traumatic brain injury with such biological properties. There is also a strong Immuno-modulation and rather than suppressing inflammation globally (which can hinder healing), our compound reprograms the immune system to reduce harmful effects while en-hancing repair an original and unique approach to TBI.
We have a strong preclinical efficacy as the compound shows significant improvement in cognitive and motor functions in animal models. In addition we have a sustainable bioproduction. Indeed the drug is derived from renewable marine biomass, avoiding synthetic or animal-based sourcing.
Our company uses a circular bioeconomy model, valorizing co-products from extraction for other industries (cosmetics, nutraceutical), which reduces waste and adds revenue streams. Last, we have a broad therapeutic potential. While initially developed for TBI, the mechanism of action could be relevant for other neuroinflammatory or neurodegenerative condi-tions, such as multiple sclerosis or Alzheimer’s disease, opening doors for future pipeline expansion. - Technical Specification or Expertise Sought
-
The partner’s role would involve:
• Characterizing and developing product lines derived from these co-products, such as bioactive skincare ingredients, functional food supplements, or natural biostimu-lants,
• providing industrial scaling and formulation expertise to transform raw marine co-products into standardized, value-added ingredients,
• Navigating regulatory landscapes to ensure market readiness,
• Co-investing in industrial valorization platforms, if relevant, to secure production capacity and supply chain resilience.
Our company offers access to a sustainable, renewable marine biomass source and a proprietary extraction process already optimized for pharmaceutical standards.
*** The ideal partner will have a strong presence in natural product markets, a commitment to sustainable innovation, and the capacity to turn high-quality marine by-products into differentiated high value products with commercial impact. *** - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
- IPR notes
- + already granted
Partner Sought
- Expected Role of a Partner
-
Commercial partner to valorize the co-products generated during the extraction and purification of its marine-derived active pharmaceutical ingredient.
These co-products, rich in marine polysaccharides, proteins, and antioxidants, present high potential for applications in the cosmetic, nutraceutical sectors.
The partner’s role would involve:
• Characterizing and developing product lines derived from these co-products, such as bioactive skincare ingredients, functional food supplements, or natural biostimulants,
• providing industrial scaling and formulation expertise to transform raw marine co-products into standardized, value-added ingredients,
• Navigating regulatory landscapes to ensure market readiness,
• Co-investing in industrial valorization platforms, if relevant, to secure production capacity and supply chain resilience.
We offer access to a sustainable, renewable marine biomass source and a proprietary extraction process already optimized for pharmaceutical standards.
The ideal partner will have a strong presence in natural product markets, a commitment to sustainable innovation, and the capacity to turn high-quality marine by-products into differentiated high value products with commercial impact. - Type and Size of Partner
- SME <=10
- SME 11-49
- SME 50 - 249
- Big company
- R&D Institution
- University
- Type of partnership
- Commercial agreement
- Investment agreement
Dissemination
- Market keywords
- 05003005 - Drug delivery and other equipment
- 05007002 - Pharmaceuticals/fine chemicals
- Sector Groups Involved
- Health
- Targeted countries
- All countries